# **Biocartis** H1 2017 results and business update

7 September 2017



#### NOTICES AND WARNINGS

This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. It is not a prospectus or offering memorandum.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation. In addition, even if the company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation. In addition, even if the company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation. In addition, even if the company operates may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements are based, except as required by applicable law or regulation.

This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

The Company's securities have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.



### Today's presenters



Hilde Windels Executive Director



Ewoud Welten Chief Financial Officer



Herman Verrelst Chief Executive Officer



### High **precision** diagnostics for personalized medicine



- Combining advantages of point-of-care testing with the quality of lab reference testing
  - High sensitivity
  - High levels of multiplexing
  - Unsurpassed ease of use
  - Fast time-to-result
  - Any clinical sample type (including FFPE<sup>1</sup>)
- Fully automated sample-to-result allowing for 'first time right' results

BIOCARTIS

# Key messages H1 2017 results

Commercial product revenues:

Commercial cartridge consumption:

Installed base:

Menu of tests:

Cash position:

Guidance:

Year-over-year growth of 195%

Exceeded full year 2016 volume

Close to 500 Idylla<sup>™</sup> instruments per end H1 2017

Two new CE-markings and launch third liquid biopsy


EUR 59.0m

Full year guidance reiterated



### Idylla™ follows a **razor-razorblade** model

Test menu expansion



Instrument installed base growth


- Cartridge consumption on Idylla<sup>™</sup> instruments will be the key value driver of Biocartis
- A broad installed base of Idylla<sup>™</sup> instruments with expanding Idylla<sup>™</sup> test menu facilitates cartridge consumption

- Focus H1 2017 on further growth of cartridge consumption through expansion of:
  - Idylla<sup>™</sup> menu internal and third party development
  - Commercial footprint installed base growth in existing markets and launches in new markets



### Idylla<sup>TM</sup> installed base close to 500 end H1 2017

#### Installed base development



#### Remarks

- Key drivers H1 2017 installed base growth:
  - Fully CE-marked solid biopsy RAS offering for mCRC on market since end 2016
  - O CE-marking Idylla™ EGFR Mutation Test in June 2017
- Strong placements in both the European and RoW<sup>1</sup> markets



### Continued accelerated growth of cartridge volume

End June 2016	End June 2017	Cartridge volume
Installed base 271	Installed base 497	H1 2017 commercial volume increased to approx. 27,000 cartridges
Idylla™ tests 7	Idylla™ tests 12	Volume H1 2017 exceeded the total volume for the full year 2016
CE Of which CE-marked tests 3	CE Of which CE-marked tests 6	




### Commercial product revenues increased **195%** in H1 2017

Breakdown product revenues (in EUR 1,000)			Breakdown total operating income		
By type	H1 2017	H1 2016	In EUR 1,000	H1 2017	H1 2016
Commercial revenue	5,024	1,705	Product sales revenue	5,092	2,711
R&D revenue	67	1,006	Collaboration revenue	710	2 277
Product sales revenue	5,092	2,711	Collaboration revenue	716	3,377
		Service revenue	104	20	
By product	H1 2017	H1 2016	Total revenue	5,912	6,109
Idylla™ System Sales	1,821	988	Grants and other income	1,066	641
Cartridge Sales	3,270	1,723		1,000	110
Product sales revenue	5,092	2,711	Total operating income	6,978	6,750



### H1 2017 net result of EUR -24m





# Cash position of EUR 59m end of H1 2017

#### Condensed cash flow statement

H1 2017	H1 2016
(23,982)	(23,784)
2,428	2,393
230	235
(21,324)	(21,156)
(848)	(4,189)
(22,172)	(25,345)
(1,531)	(6,912)
(479)	3,919
(24,182)	(28,338)
59,042	75,757
33,279	16,544
	(23,982) 2,428 230 (21,324) (848) (22,172) (1,531) (479) (24,182)

#### 1. Including EUR 1.2 million restricted cash related to KBC Lease financing


2. Current portion of EUR 4.0m

#### Remarks

- Cash flow from operating activities improved year-over-year as the result of:
  - A year-over-year stable operational burn rate
  - Modest investments in working capital for H1 2017 compared to material movements in working capital for H1 2016
- Cash flow from investing activities in H1 2017:
  - Mainly related to capitalized Idylla<sup>™</sup> systems placed with customers under (reagent) rental agreements and Idylla<sup>™</sup> systems used for internal needs
  - Note: The EUR 1.8m investments for cartridge manufacturing expansion in H1 2017 were directly paid via lease financing
- Cash flow from financing activities in H1 2017 relates to repayment of borrowings
- Total net cash flow in H1 2017 of EUR -24.2m



# Broad offering for **colorectal cancer**



Depicts assays that are launched.
 CE = CE-marked tests. RUO = Resear
 I. Ferlay J, Soerjomataram I, Ervik M
 BIOCARTIS 2. Jean-Yyes Douillard M D. Ph.D.

CE = CE-marked tests. RUO = Research Use Only, not for diagnostic procedures. Depicted products are not for sale in the USA and Canada.

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality

2. Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34

# Powerful tests for lung cancer

#### Lung cancer testing

- Lung cancer is most common cancer worldwide accounting for 13% of all cancer types<sup>1</sup>, 85% of lung cancers are non-small cell lung cancers (NSCLC)<sup>2</sup>
- Today, EGFR mutation testing is recommended in all patients with advanced NSCLC of a non-squamous subtype<sup>3</sup>
- Current molecular testing of lung cancer samples is a complex process:
  - Can take up to several weeks<sup>4</sup>
  - Samples are often small, with a limited amount of available lung tumor tissue
  - Laboratories send out samples for testing, causing long waiting times

#### Idylla<sup>™</sup> EGFR Mutation Test

- Solid biopsy test
- CE-marked in June 2017
- Only on market fully automated CE-IVD test detecting all relevant EGFR mutations according to international guidelines

#### Idylla<sup>™</sup> ctEGFR Mutation Assay



- Liquid biopsy test, under development. Aimed for launch end of 2017
- Same panel as solid biopsy test (51 EGFR mutations)
- Operates directly from plasma



- 1. Navani et al. Lancet Respir Med (2015)
- 2. American Cancer Society. Global Cancer Facts & Figures 2nd Edition (2011)

3. NCCN Clinical Practice Guidelines in Oncology – NSCLC – Version 6.2017. Novello S. et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2016 4. Neal I. Lindeman et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (2014).

### Initiated breast cancer menu development with partners

Test	Description	Partner	Partnership structure	
Resistance monitoring test	<ul> <li>Liquid biopsy test</li> <li>Monitoring of metastatic breast cancer patients for resistance to hormone therapy</li> </ul>	lifeArc	<ul> <li>Development multiple Idylla<sup>™</sup> tests</li> <li>LifeArc acts as development contractor</li> <li>Biocartis responsible for commercialization under own label</li> </ul>	
lesi		UK based medical research charity <sup>1</sup>		
Therapy selection test	<ul> <li>Solid biopsy test</li> <li>Supporting optimal therapy selection decisions for breast cancer patients</li> </ul>	Agency for Science, Technology and Research Singapore's Agency for Science, Technology and Research <sup>2</sup>	<ul> <li>Parties will co-invest in development of selected Idylla<sup>™</sup> tests</li> <li>A*STAR acts as development partner</li> <li>Biocartis responsible for commercialization under own label</li> </ul>	



1. On 15 June 2017 MRC Technology changed its name in LifeArc. LifeArc has been involved in helping deliver a number of therapies including Keytruda (pembrolizumab, marketed by MSD) which is an important immunotherapy treatment for various cancers.

### Promising MSI test to be launched in 2018

#### Background

 Microsatellite instability (MSI) is the consequence of errors in the body's so-called DNA mismatch repair system, resulting in potential tumor growth



- Initial target markets for MSI testing:
  - Recommended in several guidelines<sup>1</sup> for CRC (present in several other tumor types as well, such as gastric cancer)
  - $\circ~$  Could be the sole independent factor to predict a patient's response to certain immunotherapies^2 for oncology
- Biocartis' MSI test:
  - $_{\odot}~$  Is based on exclusively licensed biomarkers from the VIB^3
  - $\circ~$  Does not require sample control; only 1 FFPE slice per patient required

#### Performance data licensed MSI Biomarkers<sup>3</sup> (Reference method ('RM') is Promega MSI analysis)

• Included 870 samples

CRC samples<sup>4</sup>

Ц

gastric samples<sup>5</sup>

- 94% overall agreement with RM (discordance testing showed that MSI Biomarkers detected 6% more MSIhigh status)
- 12% of the tests performed with RM failed, even after repeat testing, compared to 4% with MSI Biomarkers
- Included 150 samples (study in collaboration with Merck KGaA)
- 100% overall agreement with RM for valid results
- 11% of samples tested with RM failed, even after repeat testing, MSI Biomarkers generated a result in 100% of the tests



1. NCCN Guidelines Colon Cancer version 2017.1; and, Van Cutsem et al. (2016) ESMO Consensus Guidelines for the management of patients with mCRC. Annals of Oncology 27, 1386–1422

2. Recent data have shown that advanced CRC patients with an MSI-high status respond particularly well to certain immunotherapies (Xiao Y et al. (2015)

3. Exclusive license agreement with the Flemish Institute for Biotechnology (VIB) for rt-PCR compatible MSI markers (the "MSI Biomarkers")

BIOCARTIS 4. Maertens et al., "Detection of microsatellite instability (MSI) in colorectal cancer samples with the automated Idylla<sup>TM</sup> MSI Test", 2017, to be presented as ESMO, 8-12 September 2017, Madrid, Spain 5. De Craene et al., "Detection of microsatellite instability (MSI) with a novel panel of biomarkers in gastric cancer samples", 2017, to be presented as ESMO, 8-12 September 2017, Madrid, Spain

# US commercialization launched

#### Commercialization update

- US General Manager and core US support team hired
- Sales force training Thermo Fisher Scientific ongoing
- US subsidiary established
- US FDA 510k exemption Idylla<sup>™</sup> instrumentation and first test cleared by US FDA
- First US commercial placements concluded

#### Partnership Thermo Fisher Scientific

#### **ThermoFisher** SCIENTIFIC

- Partnership signed with Fisher Healthcare, a division of Thermo Fisher Scientific Inc.
- Thermo Fisher to act as distributor in the US<sup>1</sup>, Biocartis retains right to sell directly
- Initial focus on distribution of Idylla™ oncology products
- 5 year initial term

US expected to account for the largest proportion of the MDx market for oncology (expected market size of \$1.45B by 2020) and infectious disease (expected market size of \$1.07B by 2020)<sup>2</sup>

# Guidance 2017 reiterated



250 - 275 expected installed base expansion in 2017 Forecasted total installed base of Idylla<sup>™</sup> instruments around 640 by year-end



Commercial cartridge volume in 2017 to be at least three times 2016 volume



Guidance target cash position by end 2017 of around EUR 40m



# Expected menu **Newsflow** 2017

- CE-marking Idylla<sup>™</sup> EGFR Mutation Test
- CE-marking Idylla<sup>™</sup> NRAS Mutation Test
- US FDA 510(k) approval of the Idylla<sup>™</sup> Respiratory (IFV-RSV) Panel<sup>1</sup>
- CE-marking Idylla<sup>™</sup> ctKRAS Mutation Test (Q4 2017)
- CE-marking Idylla<sup>™</sup> ctNRAS-BRAF Mutation Test (Q4 2017)
- Launch Idylla<sup>™</sup> ctEGFR Mutation Assay (RUO, Q4 2017)





### Financial Calendar 2017

- Extraordinary Shareholders Meeting Biocartis
- Q3 2017 business update
- 2017 full year results
- Publication 2017 annual report

11 September 2017

16 November 2017

1 March 2018

5 April 2018



# Q&A



